Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Aptiom® (eslicarbazepine) – Expanded indication, new warning
September 14, 2017 – Sunovion announced the FDA approval of Aptiom (eslicarbazepine), for the treatment of partial-onset seizures in patients 4 years of age and older.
